A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: 1. Histologically or cytologically confirmed, Stage IIIB/IIIC or IV non-squamous NSCLC 2. Participants with no EGFR, ALK and ROS1 mutation. 3. Participants with no prior treatment for Stage IIIB/IIIC or IV non-squamous NSCLC 4. Measurable disease as defined by RECIST v1.1 5. Eastern Cooperative Oncology Group performance status 0 or 1 6. Adequate hematologic and end organ function Exclusion Criteria: 1. Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome 2. Active central nervous system metastases 3. Prior treatment with cluster of differentiation immune checkpoint blockade therapies or Bevacizumab 4. Has received a surgical operation within 4 weeks from the initial drug administration 5. Active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll. 6. Currently having or have had interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity 7. Any active infection requiring systemic anti-infective therapy within 14 days prior to study drug administration 8. Uncontrollable active infection(s) 9. History of immunodeficiency, including HIV antibody positive 10. active hepatitis B; or hepatitis C virus infections 11. Has bleeding tendency 12. History of severe cardiovascular diseases 13. Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or \> moderate esophageal varices 14. Pregnant or breastfeeding female